A compound represented by Formula (1):

##STR00001##

The compound can be used as insecticides.

A compound represented by Formula (1):

##STR00001##

The compound can be used as insecticides.

Benzyl derivative compounds having peroxisome proliferator-activated receptor α (PPARα) agonistic activity, compositions containing such compounds, and methods of their use in enhancing PPARα activity for treating diseases and/or conditions involving inflammation and/or angiogenesis, particularly ocular diseases and/or conditions such as but not limited to retinal inflammation, retinal neovascularization, retinal vascular leakage, retinopathy of prematurity, diabetic retinopathy, age-related macular degeneration, and diabetic macular edema are disclosed.

Benzyl derivative compounds having peroxisome proliferator-activated receptor α (PPARα) agonistic activity, compositions containing such compounds, and methods of their use in enhancing PPARα activity for treating diseases and/or conditions involving inflammation and/or angiogenesis, particularly ocular diseases and/or conditions such as but not limited to retinal inflammation, retinal neovascularization, retinal vascular leakage, retinopathy of prematurity, diabetic retinopathy, age-related macular degeneration, and diabetic macular edema are disclosed.

Disclosed herein are compounds, 3,4,6,8-substituted-2-([1,1′-biphenyl]-4-yl)quinoline analogs, that are inhibitors of dihydroorotate dehydrogenase (DHODH) with improved pharmacokinetic properties. The disclosed compounds can be used in the treatment of a variety of disorders and diseases in which inhibition of DHODH can be clinically useful, including cancer, such as a hematological cancer, including acute myeloid leukemia (AML); graft-versus-host-diseases; autoimmune disorders; and disorders associated with T-cell proliferation. The disclosed compounds can demonstrate flip-flop kinetics when administered orally, i.e., pharmacokinetics in which the rate of absorption, rather than the rate of elimination, dominates the pharmacokinetics. The disclosed compounds can demonstrate a sustained pharmacokinetic profile instead of an immediate release profile. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

Disclosed herein are compounds, 3,4,6,8-substituted-2-([1,1′-biphenyl]-4-yl)quinoline analogs, that are inhibitors of dihydroorotate dehydrogenase (DHODH) with improved pharmacokinetic properties. The disclosed compounds can be used in the treatment of a variety of disorders and diseases in which inhibition of DHODH can be clinically useful, including cancer, such as a hematological cancer, including acute myeloid leukemia (AML); graft-versus-host-diseases; autoimmune disorders; and disorders associated with T-cell proliferation. The disclosed compounds can demonstrate flip-flop kinetics when administered orally, i.e., pharmacokinetics in which the rate of absorption, rather than the rate of elimination, dominates the pharmacokinetics. The disclosed compounds can demonstrate a sustained pharmacokinetic profile instead of an immediate release profile. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

The invention provided methods of treating viral infections, such as COVID-19, by providing an agent that inhibits a nucleotide synthesis pathway. In certain methods, the agent is an inhibitor of dihydroorotate dehydrogenase, such as a brequinar. In certain methods, brequinar is provided to a subject according to a dosing regimen that tailors levels of the drug in the lungs to achieve optimal therapeutic benefit. The dosing regimen may include defined levels of brequinar administered to the subject or defined levels of brequinar attained the lungs of the subject. The invention also provides combination therapies in which an inhibitor of dihydroorotate dehydrogenase is provided together with a second therapeutic agent.

The invention provided methods of treating viral infections, such as COVID-19, by providing an agent that inhibits a nucleotide synthesis pathway. In certain methods, the agent is an inhibitor of dihydroorotate dehydrogenase, such as a brequinar. In certain methods, brequinar is provided to a subject according to a dosing regimen that tailors levels of the drug in the lungs to achieve optimal therapeutic benefit. The dosing regimen may include defined levels of brequinar administered to the subject or defined levels of brequinar attained the lungs of the subject. The invention also provides combination therapies in which an inhibitor of dihydroorotate dehydrogenase is provided together with a second therapeutic agent.

A compound represented by Formula (1):

##STR00001##

The compound can be used as insecticides.

A compound represented by Formula (1):

##STR00001##

The compound can be used as insecticides.